Available Technologies


294 available technologies

PosiSeat™: Assured Seating of Threaded Surgical Components

Vanderbilt presents an intraoperative device for taking the guesswork out of whether or not a threaded component is securely affixed to bone. This device is an anchor driver that automatically releases upon proper seating of the anchor on the bone of interest.

MultiUse Multimodal Imaging Chelates

PK11195 is a high-affinity ligand of the peripheral benzodiazepine receptor (PBR). By linking lanthanide chelates to the PK11195 targeting moiety, Vanderbilt researchers have generated a range of PBR-targeted imaging probes capable of visualizing a number of disease states at cellular levels using a variety of imaging modalities (fl uorescence, PET and SPECT, MRI, electron microscopy).

Patent Ductus Arteriosus Stent

Vanderbilt researchers have created a low-cost, removable Patent Ductus Arteriosus (PDA) stent for pediatric patients. There is currently no commercially available pediatric PDA stent, but it is estimated that over 3,000 babies are born each year in the United States with cyanotic heart disease; a significant fraction of whom can benefit from temporary placement of the PDA stent described here.

Peptide and Protein Fragmentation by Lysine Residue Originated Reactions

A method of modifying protein samples that comprises combining the sample with a peroxycarbonate solution and inserting the sample into a mass spectrometer. The present invention also includes methods of N-terminus characterization.

Human Monoclonal Antibodies to Infectious Diseases

Using human B cell hybridoma creation, and antibody engineering technologies, Dr. James E Crowe Jr.'s laboratory has developed an array of antibodies from full length human antibodies to Fab fragments and diabodies. Many of these antibodies are ready for a cooperate partner who can further develop these antibodies into biologic herapeutics. The table below is a sample of the antibodies they are currently researching and have available. In addition to these areas of research, Dr. Crowe is actively seeking collaborative opportunities to identify new interesting targets for future antibody engineering projects.

Molecular Profiles for Subtyping Triple Negative Breast Cancer

Personalized medicine is at the forefront of medical news and specialized diagnostics that can align patients with the correct treatment are the key to this type of medicine. Jennifer Pietenpol and colleagues have performed extensive research and discovered that triple negative breast cancer (TNBC) is a heterogeneous disease with at least six subtypes. These subtypes have differing biological behaviors and sensitivities to known therapeutics. Diagnostic assays will help guide personalized and more effective therapy.

Multisubstrate Inhibitors of Histone Acetylation Increase the Cytotoxicity of Chemotherapeutic Agents

Inhibitors of histone acetylation may constitute a novel class of potent therapy sensitizers applicable to a broad range of conventional cancer treatments.

Motion Generator to Transform Linear into Nutation Motion

This novel device converts linear motion into nutating motion and can create large angles from small linear displacements. The invention uniquely provides control and precision in the use of nutation motion making it particularly adaptable to micro-applications.

A Novel Method for Importing Peptides with Functional Cargo Into the Cells

This technology enables the delivery of biological molecules into the interior of a cell. Such a delivery mechanism could be utilized in a variety of therapies including peptide, gene transfer and/or antisense therapy.

Chemical Sensor Utilizing a Chemically Sensitive Electrode in Combination with Thin Diamond Layers

Vanderbilt researchers have developed a novel solid state chemical sensor using CVD diamond film. The system utilizes polycrystalline diamond technology combined with chemically-sensitive electrode layers to achieve high sensitivity and selectivity for a variety of chemical species.

New NSAIDs derivatives for cancer treatment - Protective and less toxic, targeting PPAR gamma

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely-used anti-inflammatory and anti-pyretic therapeutic agents to treat human diseases. However, long-term use of NSAIDs comes with risks. Many NSAIDs are COX-1 inhibitors, which are associated with significant GI toxicities. The Marnett Lab at Vanderbilt University has developed new derivatives of NSAIDs that retain their protective effects but do not cause debilitating and potentially fatal toxicities.

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter